[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564146":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":41,"responsibleParty":57,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":24,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":44,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Shahid Beheshti University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SMOF lipid","EXPERIMENTAL","The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.",[13],"Dietary Supplement: SMOF lipid",{"label":15,"type":16,"description":17,"interventionNames":18},"Intralipid","ACTIVE_COMPARATOR","intralipids",[19],"Dietary Supplement: INTRALIPIDS",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT",[9],null,{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"INTRALIPIDS","The Intralipid will be given to the patient as fat component of total parenteral nutrition.",[15],[30],{"name":31,"affiliation":32,"role":33},"Zahra Vahdat Shariatpanahi, Professor","School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","0098-021-22357484","nutritiondata@yahoo.com",{"name":31,"role":36,"phone":40,"phoneExt":24,"email":38},"09122138186",[42],{"facility":43,"status":44,"city":45,"state":24,"zip":24,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran","RECRUITING","Tehran","Iran","IR",{"type":49,"coordinates":50},"Point",[51,52],51.42151,35.69439,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":24,"phoneExt":24,"email":24},"Amirali hamidieh",{"type":33,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Zahra Vahdat Shariatpanahi","Associate professor","100564146","comparison-of-intralipid-with-smof-lipid-following-hsct-100564146",false,"NCT06625372","Comparison of Intralipid With SMOF Lipid Following HSCT","Comparison of the Effect of Intralipid Parenteral Nutritional With SMOF Lipid Parenteral Nutritional on Biochemical Markers, Hematologic Markers, and Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","Inclusion Criteria:\n\n* Willingness to cooperate and complete the informed consent form by the legal guardian of the child;\n* Age ≤ 18 years;\n* Definitive diagnosis of acute leukemia and candidate for hematopoietic stem ● cell transplantation;\n* Eligible for parenteral nutrition support;\n* No contraindications for parenteral nutrition;\n* No history of allergy to egg or soy protein;\n* Absence of severe organ failure or impaired liver function test (bilirubin \\> 2.5 mg\u002FdL).\n\nExclusion Criteria:\n\n* Death of the child earlier than 5 days from the start of the intervention;\n* Unwillingness to continue cooperation during study;\n* Occurrence of side effects during the study;\n* In case of sepsis, hypotension, shock, thrombosis, myocardial infarction, liver dysfunction, the patient will be excluded from the study.","ALL","2 Years","18 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.",[78,79],"Leukemia","HSCT",[81,82,15,83,84],"mortality","SMOF","Engrafment","Complications","2024-10-12",{"date":87,"type":88},"2024-10-16","ACTUAL",{"date":85,"type":88},{"date":91,"type":72},"2025-12",{"name":5,"class":6},1]